Intellistem, Inc. is global Biotech with operations in the U.S., Canada, the UK, Germany, and

Advisors stretched globally. We have an exceptional team with direct scientific, clinical, and

development experience in cell therapy. They are experts at translating basic cell therapy

research into workable medical interventions for patients in a regulatory-compliant, quality-

managed system.

At each stage in our development, we forge new collaborations with leading strategic partners

and top medical centers to accelerate the development of our first-in-class cell therapy

product.

Particular emphasis on clinical application and producing the therapeutic product

Adthera focuses on cell therapy development and cGMP-compliant manufacturing of cells for clinical trials and commercialization. 

The first manufacturing run of SSC produced sufficient cells to support clinical trial commercialization. Following registration, the same methods will be used in the commercial manufacture of SSC cells.

The methods, materials, and processes are trade secrets.

Feature 3

Moutih Rafei, PH.D. is a professor at the University of Montreal and a founding Intellistem team member.

His lab is researching new applications for the SSC cell platform and performing IND -enabling studies.